Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-01-2013 | Article

Extended-spectrum β-lactamase-producing Enterobacteriaceae in Cameroonian hospitals

Authors: C. M. Lonchel, P. Melin, J. Gangoué-Piéboji, M.-C. O. Assoumou, R. Boreux, P. De Mol

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 1/2013

Abstract

Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae have been described worldwide, but there are few reports on the carriage of these bacteria in Cameroon. In order to investigate the types of ESBLs and to analyse some risk factors associated with ESBL carriage, faecal samples were collected between 3 January and 3 April 2009 from hospitalised patients at Yaounde Central Hospital and at two hospitals in Ngaoundere, Cameroon. Enterobacterial isolates resistant to third-generation cephalosporins were screened for ESBL production using the double-disk synergy test. Polymerase chain reaction (PCR) and DNA sequencing were performed in order to find out the different types of ESBL genes in presumptive ESBL-positive isolates. During the study period, a total of 121 different patients were screened for ESBL carriage. The prevalence among these patients whose faecal samples were found to contain ESBL-producers was 55.3 % (67/121). According to a univariate analysis, hospitalisation during the previous year was found to be associated with ESBL carriage. Of the 71 bacteria isolated, Escherichia coli was predominant and represented 48 % of all isolates. ESBL characterisation revealed two types of ESBLs, CTX-M-15 (96 %) and SHV-12 (4 %). The present study emphasises the importance of screening for ESBLs in laboratories in African countries. The monitoring and detection of ESBL-producing bacteria are important in the setting up of appropriate treatment of patients and to ensure effective infection control efforts.

Song W, Kim J, Bae IK, Jeong SH, Seo YH, Shin JH, Jang SJ, Uh Y, Shin JH, Lee MK, Lee K (2011) Chromosome-encoded AmpC and CTX-M extended-spectrum beta-lactamases in clinical isolates of Proteus mirabilis from Korea. Antimicrob Agents Chemother 55(4):1414–1419PubMedCrossRef

Fabre L, Delaune A, Espie E, Nygard K, Pardos M, Polomack L, Guesnier F, Galimand M, Lassen J, Weill FX (2009) Chromosomal integration of the extended-spectrum beta-lactamase gene blaCTX-M-15 in Salmonella enterica serotype Concord isolates from internationally adopted children. Antimicrob Agents Chemother 53(5):1808–1816PubMedCrossRef

Cantón R, González-Alba JM, Galán JC (2012) CTX-M enzymes: origin and diffusion. Front Microbiol 3:110PubMed

Rahal JJ (2000) Extended-spectrum beta-lactamases: how big is the problem? Clin Microbiol Infect 6(Suppl 2):2–6PubMedCrossRef

Colodner R, Raz R (2005) Extended-spectrum beta-lactamases: the end of cephalosporins? Isr Med Assoc J 7(5):336–338PubMed

Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S (1983) Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11(6):315–317PubMedCrossRef

Breurec S, Guessennd N, Timinouni M, Le TA, Cao V, Ngandjio A, Randrianirina F, Thiberge JM, Kinana A, Dufougeray A, Perrier-Gros-Claude JD, Boisier P, Garin B, Brisse S (2012) Klebsiella pneumoniae resistant to third-generation cephalosporins in five African and two Vietnamese major towns: multiclonal population structure with two major international clonal groups, CG15 and CG258. Clin Microbiol Infect. [Epub ahead of print]

Gangoué-Piéboji J (2007) Caractérisation des beta-lactamases et leur inhibition par les extraits de plantes médicinales. BICTEL/e—ULG Serveur institutionnel des thèses de doctorat

Gangoué-Piéboji J, Bedenic B, Koulla-Shiro S, Randegger C, Adiogo D, Ngassam P, Ndumbe P, Hächler H (2005) Extended-spectrum-beta-lactamase-producing Enterobacteriaceae in Yaounde, Cameroon. J Clin Microbiol 43(7):3273–3277PubMedCrossRef

10.

Jarlier V, Nicolas MH, Fournier G, Philippon A (1988) Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 10(4):867–878PubMedCrossRef

11.

Clinical and Laboratory Standards Institute (CLSI) (2010) Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI document M100-S20. CLSI, Wayne, PA

12.

Dallenne C, Da Costa A, Decré D, Favier C, Arlet G (2010) Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother 65(3):490–495PubMedCrossRef

13.

Pagani L, Dell’Amico E, Migliavacca R, D’Andrea MM, Giacobone E, Amicosante G, Romero E, Rossolini GM (2003) Multiple CTX-M-type extended-spectrum beta-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in northern Italy. J Clin Microbiol 41(9):4264–4269PubMedCrossRef

14.

Bomasang ES, Mendoza MT (2003) Prevalence and risk factors associated with extended spectrum beta lactamase (ESBL) production among selected Enterobacteriaceae isolates at the Philippine General Hospital. Phil J Microbiol Infect Dis 32:151–158

15.

Tonkic M, Goic-Barisic I, Punda-Polic V (2005) Prevalence and antimicrobial resistance of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumoniae strains isolated in a university hospital in Split, Croatia. Int Microbiol 8(2):119–124PubMed

16.

Ramazanzadeh R, Mansouri M (2009) Spread of extended-spectrum beta-lactamase producing Escherichia coli clinical isolates in Sanandaj hospitals. J Biol Sci 9:362–366CrossRef

17.

Machado E, Coque TM, Cantón R, Novais A, Sousa JC, Baquero F, Peixe L; Portuguese Resistance Study Group (2007) High diversity of extended-spectrum beta-lactamases among clinical isolates of Enterobacteriaceae from Portugal. J Antimicrob Chemother 60(6):1370–1374PubMedCrossRef

18.

Severin JA, Mertaniasih NM, Kuntaman K, Lestari ES, Purwanta M, Lemmens-Den Toom N, Duerink DO, Hadi U, van Belkum A, Verbrugh HA, Goessens WH; Study Group ‘Antimicrobial Resistance in Indonesia: Prevalence and Prevention’ (AMRIN) (2010) Molecular characterization of extended-spectrum beta-lactamases in clinical Escherichia coli and Klebsiella pneumoniae isolates from Surabaya, Indonesia. J Antimicrob Chemother 65(3):465–469PubMedCrossRef

19.

Ahoyo AT, Baba-Moussa L, Anago AE, Avogbe P, Missihoun TD, Loko F, Prévost G, Sanni A, Dramane K (2007) Incidence of infections dues to Escherichia coli strains producing extended spectrum betalactamase, in the Zou/Collines Hospital Centre (CHDZ/C) in Benin. Med Mal Infect 37(11):746–752PubMedCrossRef

20.

Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DS, Urassa WK, Fataki M, Msangi V, Tellevik MG, Maselle SY, Langeland N (2005) High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol 43(2):745–749PubMedCrossRef

21.

Seid J, Asrat D (2005) Occurrence of extended spectrum beta-lactamase enzymes in clinical isolates of Klebsiella species from Harar region, eastern Ethiopia. Acta Trop 95(2):143–148PubMedCrossRef

22.

Mirelis B, Navarro F, Miró E, Mesa RJ, Coll P, Prats G (2003) Community transmission of extended-spectrum beta-lactamase. Emerg Infect Dis 9(8):1024–1025PubMedCrossRef

23.

Smith DL, Dushoff J, Perencevich EN, Harris AD, Levin SA (2004) Persistent colonization and the spread of antibiotic resistance in nosocomial pathogens: resistance is a regional problem. Proc Natl Acad Sci USA 101(10):3709–3714PubMedCrossRef

24.

Lonchel CM, Meex C, Gangoué-Piéboji J, Boreux R, Okomo Assoumou MC, Melin P, De Mol P (2012) Proportion of extended-spectrum β-lactamase-producing Enterobacteriaceae in community setting in Ngaoundere, Cameroon. BMC Infect Dis 12(1):53PubMedCrossRef

25.

Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, Raz R (2004) Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 23:163–167PubMedCrossRef

26.

Andriatahina T, Randrianirina F, Hariniana ER, Talarmin A, Raobijaona H, Buisson Y, Richard V (2010) High prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric unit in Madagascar. BMC Infect Dis 10:204PubMedCrossRef

27.

Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, Vila J, Garau J (2006) Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 57(4):780–783PubMedCrossRef

28.

Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, Pérez-Cano R, Pascual A (2004) Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 42:1089–1094PubMedCrossRef

29.

Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO (2001) Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32(8):1162–1171PubMedCrossRef

30.

Kuster SP, Hasse B, Huebner V, Bansal V, Zbinden R, Ruef C, Ledergerber B, Weber R (2010) Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection 38(1):33–40PubMedCrossRef

31.

Fam N, Leflon-Guibout V, Fouad S, Aboul-Fadl L, Marcon E, Desouky D, El-Defrawy I, Abou-Aitta A, Klena J, Nicolas-Chanoine MH (2011) CTX-M-15-producing Escherichia coli clinical isolates in Cairo (Egypt), including isolates of clonal complex ST10 and clones ST131, ST73, and ST405 in both community and hospital settings. Microb Drug Resist 17(1):67–73PubMedCrossRef

32.

Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, Leavitt A, Carmeli Y (2006) Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis 42(7):925–934PubMedCrossRef

33.

Gangoué-Piéboji J, Koulla-Shiro S, Ngassam P, Adiogo D, Ndumbe P (2006) Antimicrobial activity against gram negative bacilli from Yaounde Central Hospital, Cameroon. Afr Health Sci 6(4):232–235PubMed

34.

Peirano G, van Greune CH, Pitout JD (2011) Characteristics of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli from community hospitals in South Africa. Diagn Microbiol Infect Dis 69(4):449–453PubMedCrossRef

35.

Drieux L, Brossier F, Duquesnoy O, Aubry A, Robert J, Sougakoff W, Lecso-Bornet M, Jarlier V (2009) Increase in hospital-acquired bloodstream infections caused by extended spectrum beta-lactamase-producing Escherichia coli in a large French teaching hospital. Eur J Clin Microbiol Infect Dis 28(5):491–498PubMedCrossRef

36.

Silva J, Aguilar C, Becerra Z, López-Antuñano F, García R (1999) Extended-spectrum beta-lactamases in clinical isolates of enterobacteria in Mexico. Microb Drug Resist 5(3):189–193PubMedCrossRef

37.

Ho PL, Poon WW, Loke SL, Leung MS, Chow KH, Wong RC, Yip KS, Lai EL, Tsang KW; COMBAT study group (2007) Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary Escherichia coli from women. J Antimicrob Chemother 60(1):140–144PubMedCrossRef

38.

Ndugulile F, Jureen R, Harthug S, Urassa W, Langeland N (2005) Extended spectrum beta-lactamases among Gram-negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania. BMC Infect Dis 5:86PubMedCrossRef

39.

Ehlers MM, Veldsman C, Makgotlho EP, Dove MG, Hoosen AA, Kock MM (2009) Detection of blaSHV, blaTEM and blaCTX-M antibiotic resistance genes in randomly selected bacterial pathogens from the Steve Biko Academic Hospital. FEMS Immunol Med Microbiol 56(3):191–196PubMedCrossRef

40.

Touati A, Brasme L, Benallaoua S, Madoux J, Gharout A, de Champs C (2008) Enterobacter cloacae and Klebsiella pneumoniae isolates producing CTX-M-15 recovered from hospital environmental surfaces from Algeria. J Hosp Infect 68(2):183–185PubMedCrossRef

41.

Touati A, Benallaoua S, Forte D, Madoux J, Brasme L, de Champs C (2006) First report of CTX-M-15 and CTX-M-3 beta-lactamases among clinical isolates of Enterobacteriaceae in Béjaia, Algeria. Int J Antimicrob Agents 27(5):397–402PubMedCrossRef

42.

Touati A, Benallaoua S, Djoudi F, Madoux J, Brasme L, De Champs C (2007) Characterization of CTX-M-15-producing Klebsiella pneumoniae and Escherichia coli strains isolated from hospital environments in Algeria. Microb Drug Resist 13(2):85–89PubMedCrossRef

43.

Olowe OA, Grobbel M, Büchter B, Lübke-Becker A, Fruth A, Wieler LH (2010) Detection of bla(CTX-M-15) extended-spectrum beta-lactamase genes in Escherichia coli from hospital patients in Nigeria. Int J Antimicrob Agents 35(2):206–207PubMedCrossRef

44.

Frank T, Arlet G, Gautier V, Talarmin A, Bercion R (2006) Extended-spectrum beta-lactamase-producing Enterobacteriaceae, Central African Republic. Emerg Infect Dis 12(5):863–865PubMedCrossRef

45.

Dahmen S, Bettaieb D, Mansour W, Boujaafar N, Bouallègue O, Arlet G (2010) Characterization and molecular epidemiology of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in a Tunisian University Hospital. Microb Drug Resist 16(2):163–170PubMedCrossRef

46.

Damjanova I, Tóth A, Pászti J, Bauernfeind A, Füzi M (2006) Nationwide spread of clonally related CTX-M-15-producing multidrug-resistant Klebsiella pneumoniae strains in Hungary. Eur J Clin Microbiol Infect Dis 25(4):275–278PubMedCrossRef

47.

Valenzuela de Silva EM, Mantilla Anaya JR, Reguero Reza MT, González Mejía EB, Pulido Manrique IY, Darío Llerena I, Velandia D (2006) Detection of CTX-M-1, CTX-M-15, and CTX-M-2 in clinical isolates of Enterobacteriaceae in Bogota, Colombia. J Clin Microbiol 44(5):1919–1920PubMedCrossRef

48.

Duval V, Maiga I, Maiga A, Guillard T, Brasme L, Forte D, Madoux J, Vernet-Garnier V, De Champs C (2009) High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. Antimicrob Agents Chemother 53(11):4957–4958PubMedCrossRef

49.

Ramdani-Bouguessa N, Mendonça N, Leitão J, Ferreira E, Tazir M, Caniça M (2006) CTX-M-3 and CTX-M-15 extended-spectrum beta-lactamases in isolates of Escherichia coli from a hospital in Algiers, Algeria. J Clin Microbiol 44(12):4584–4586PubMedCrossRef

50.

Gangoué-Piéboji J, Miriagou V, Vourli S, Tzelepi E, Ngassam P, Tzouvelekis LS (2005) Emergence of CTX-M-15-producing enterobacteria in Cameroon and characterization of a blaCTX-M-15-carrying element. Antimicrob Agents Chemother 49(1):441–443PubMedCrossRef

51.

Kariuki S, Corkill JE, Revathi G, Musoke R, Hart CA (2001) Molecular characterization of a novel plasmid-encoded cefotaximase (CTX-M-12) found in clinical Klebsiella pneumoniae isolates from Kenya. Antimicrob Agents Chemother 45(7):2141–2143PubMedCrossRef

52.

Mohamed Al-Agamy MH, El-Din Ashour MS, Wiegand I (2006) First description of CTX-M beta-lactamase-producing clinical Escherichia coli isolates from Egypt. Int J Antimicrob Agents 27(6):545–548PubMedCrossRef

Title: Extended-spectrum β-lactamase-producing Enterobacteriaceae in Cameroonian hospitals
Authors: C. M. Lonchel
P. Melin
J. Gangoué-Piéboji
M.-C. O. Assoumou
R. Boreux
P. De Mol
Publication date: 01-01-2013
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 1/2013
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-012-1717-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Unnecessary repeat Clostridium difficile PCR testing in hospitalized adults with C. difficile-negative diarrhea

Periodontal infections and community-acquired pneumonia: a case–control study

Influence of procalcitonin on decision to start antibiotic treatment in patients with a lower respiratory tract infection: insight from the observational multicentric ProREAL surveillance

Is diabetes a risk factor for central venous access port-related bloodstream infection in oncological patients?

Relatively high serum vitamin D levels do not impair the antibody response to encapsulated bacteria

Superantigen gene complement of Streptococcus pyogenes—relationship with other typing methods and short-term stability

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials